18 articles | last updated: Jul 11 23:50:07
Studies reveal low long-term adherence to GLP-1 injections, prompting a surge in the development of more convenient weight loss pills.
- Only 15% of patients continue GLP-1 injections for weight loss after two years, according to recent studies.
- Drugmakers like Pfizer and Novo Nordisk are developing oral weight loss drugs to address adherence issues.
- Oral alternatives may alleviate supply shortages and potentially lower costs compared to injectable treatments.
- Pfizer's once-daily obesity pill, danuglipron, shows promise but faces competition from rivals with more advanced trials.
- The weight loss drug market is expected to grow to $130 billion by the end of the decade.
People, Places and Things In This Story
- Glucagon-like peptide-1 receptor agonist Class of drugs
- Novo Nordisk Pharmaceutical company
- Pfizer Pharmaceutical industry company
Categories:
- Health
- Business
- Healthcare
- Finance
- Technology
- Environment
- Ethics